Pharmacokinetics of cefmetazole in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue of patients scheduled for lower gastrointestinal surgery: Dosing considerations based on site-specific pharmacodynamic target attainment

Lob, 2015, Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013, Antimicrob Agents Chemother, 59, 3606, 10.1128/AAC.05186-14 Dubinsky-Pertzov, 2019, Carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae and the risk of surgical site infection after colorectal surgery: a prospective cohort study, Clin Infect Dis, 68, 1699, 10.1093/cid/ciy768 McLaughlin, 2013, Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae, Antimicrob Agents Chemother, 57, 5131, 10.1128/AAC.00607-13 Harris, 2015, β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?, Lancet Infect Dis, 15, 475, 10.1016/S1473-3099(14)70950-8 Japanese Society of Chemotherapy and Japan Society for Surgical Infection Matsumura, 2016, In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae, Diagn Microbiol Infect Dis, 84, 322, 10.1016/j.diagmicrobio.2015.12.001 Woerther, 2018, Carbapenems and alternative β-lactams for the treatment of infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: what impact on intestinal colonisation resistance?, Int J Antimicrob Agents, 52, 762, 10.1016/j.ijantimicag.2018.08.026 Matsumura, 2015, Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremia, Antimicrob Agents Chemother, 59, 5107, 10.1128/AAC.00701-15 Takemura, 2021, Cefmetazole as an alternative to carbapenems against extended-spectrum beta-lactamase-producing Escherichia coli infections based on in Vitro and in Vivo pharmacokinetics/pharmacodynamics experiments, Pharm Res (N Y), 38, 1839, 10.1007/s11095-021-03140-7 Tomizawa, 2017, Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer, J Pharm Health Care Sci, 3, 1, 10.1186/s40780-016-0071-6 Egi, 2021, The Japanese clinical practice guidelines for management of sepsis and septic shock 2020 (J-SSCG 2020), J Intensive Care, 9, 53, 10.1186/s40560-021-00555-7 García-Gonzalez, 1998, Quantitative determination of semisynthetic cephamycins in human serum and urine by ion-exchange, reversed-phase and ion-pair chromatography, J Chromatogr A, 812, 197, 10.1016/S0021-9673(97)01292-2 Yamaoka, 1981, A pharmacokinetic analysis program (MULTI) for microcomputer, J Pharmacobio-Dyn, 4, 879, 10.1248/bpb1978.4.879 Barbour, 2014, Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches, Int J Antimicrob Agents, 43, 60, 10.1016/j.ijantimicag.2013.08.016 Kobayashi, 2015, Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics, J Infect Chemother, 21, 575, 10.1016/j.jiac.2015.04.015 Ikawa, 2007, Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients, Int J Antimicrob Agents, 30, 270, 10.1016/j.ijantimicag.2007.04.012 Ikawa, 2007, Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients, Int J Antimicrob Agents, 30, 352, 10.1016/j.ijantimicag.2007.06.001 Murao, 2017, Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment, Int J Antimicrob Agents, 50, 393, 10.1016/j.ijantimicag.2017.03.025 Ueda, 2021, Change in antimicrobial susceptibility of pathogens isolated from surgical site infections over the past decade in Japanese nation-wide surveillance study, J Infect Chemother, 27, 931, 10.1016/j.jiac.2021.03.010 Fukuchi, 2016, Cefmetazole for bacteremia caused by ESBL-producing Enterobacteriaceae comparing with carbapenems, BMC Infect Dis, 16, 427, 10.1186/s12879-016-1770-1 Komatsu, 2022, Timing of re-dosing based on population pharmacokinetic-pharmacodynamics target attainment analysis of cefmetazole in subjects undergoing lower gastrointestinal surgery, J Infect Chemother, 28, 1105, 10.1016/j.jiac.2022.03.024 Takayama, 2022, Association of serum and fat tissue antibiotic concentrations with surgical site infections in lower gastrointestinal surgery, Surgery, 171, 1000, 10.1016/j.surg.2021.10.013 Garcia Garcia, 1986, Peri-incisional and preoperative administration of cefmetazole for the prophylaxis of wound infection after appendicectomy, Int Surg, 71, 14 Ohge, 1999, An additional dose of cefazolin for intraoperative prophylaxis, Surg Today, 29, 1233, 10.1007/BF02482213 Martin, 1994, Clinical pharmacokinetics of cefotetan, Clin Pharmacokinet, 26, 248, 10.2165/00003088-199426040-00002 Forse, 1989, Antibiotic prophylaxis for surgery in morbidly obese patients, Surgery, 106, 750 Schentag, 1991, Cefmetazole sodium: pharmacology, pharmacokinetics, and clinical trials, Pharmacotherapy, 11, 2, 10.1002/j.1875-9114.1991.tb03592.x Yang, 2015, In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis producing extended-spectrum β-lactamases in China, Int J Antimicrob Agents, 45, 485, 10.1016/j.ijantimicag.2014.11.012 Phe, 2020, Optimizing pharmacokinetics-pharmacodynamics of antimicrobial management in patients with sepsis: a review, J Infect Dis, 222, S132, 10.1093/infdis/jiaa118